CPT® Code 88274

The CPT® Code 88274 refers to a laboratory test that focuses on molecular cytogenetics through the technique of interphase in situ hybridization. This procedure is essential for analyzing the genetic material of various biological samples, including bone marrow, blood, amniotic fluid, chorionic villi, and other tissues or tumors. Molecular cytogenetics is a field that examines the biology of chromosomes, encompassing their structure, functional organization, abnormalities, and variations within the genome. The interphase in situ hybridization method specifically targets the nuclei of eukaryotic cells, allowing for a detailed analysis of chromosomal characteristics. This technique employs interphase fluorescence in situ hybridization (I-FISH), which broadens the range of cell types that can be effectively analyzed. Samples for this test are typically obtained through various procedures, such as venipuncture, bone marrow aspiration, amniocentesis, chorionic villus sampling, and biopsy, which are reported separately. The analysis can provide rapid detection of chromosomal aneuploidy, particularly for chromosomes X, Y, 13, 18, and 21, in maternal amniotic fluid or chorionic villi, as well as in whole blood from infants. Additionally, the examination of bone marrow or whole blood is crucial for risk stratification in patients with newly diagnosed or relapsed multiple myeloma, detecting genomic abnormalities in chronic lymphocytic leukemia, and aiding in the diagnosis and classification of hematopoietic neoplasms presenting with eosinophilia. Furthermore, this procedure supports the diagnosis of acute lymphocytic leukemia and confirms the presence of PML-RARA translocation in acute promyelocytic leukemia. It is also utilized to exclude cryptic BCR-ABL1 rearrangements in myelogenous leukemia patients or PDGFRA abnormalities in those with neoplastic eosinophilia. The analysis of bone marrow or whole blood can help diagnose and predict aggressive morphologic features in cases of Burkitt lymphoma versus diffuse large B-cell lymphoma, as well as monitor minimal residual disease in therapy-related myelodysplastic syndrome (MDS) or acute myelogenous leukemia associated with MDS. Lastly, whole blood samples may be examined to identify significant translocations in patients newly diagnosed with acute myeloid leukemia. The specific code 88274 is applied when the analysis involves studying 25 to 99 cells, while code 88275 is designated for studies involving 100 to 300 cells.